Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy
Status:
Completed
Trial end date:
2017-02-24
Target enrollment:
Participant gender:
Summary
Background:
Background:
- IMC-A12, a new cancer treatment that has not yet been approved by the U.S. Food and Drug
Administration, is an antibody that is designed to block the effects of a protein called Type
I Insulin-Like Growth Factor (IGF-1R). IMC-A12 blocks the receptors in cells that respond to
IGF-1R, which are thought to play an important role in helping cancer cells to grow and
divide. Researchers are interested in determining whether IMC-A12 is an effective treatment
for individuals who have mesothelioma that has not responded to standard chemotherapy.
Objectives:
- To evaluate the safety and effectiveness of IMC-A12 treatment in individuals with
mesothelioma who have previously had chemotherapy.
Eligibility:
- Individuals at least 18 years of age who have been diagnosed with mesothelioma that has not
responded to chemotherapy.
Design:
- Eligible participants will be screened with a full physical examination and medical
history, blood and urine samples, and imaging studies.
- Participants will receive IMC-A12 once every 3 weeks (21-day cycle), and will be
evaluated before the start of each new cycle with blood tests and imaging studies if
needed.
- Treatment cycles will continue for as long as needed, unless severe side effects develop
or the disease progresses.